Istiratumab - Merrimack Pharmaceuticals

Drug Profile

Istiratumab - Merrimack Pharmaceuticals

Alternative Names: MM-141

Latest Information Update: 27 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 25 Jun 2018 Discontinued - Phase-II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Belgium (Parenteral)
  • 25 Jun 2018 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (Parenteral)
  • 25 Jun 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease) in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top